Sanofi

Sanofi

SAN.PA

€73.56

Updated: 23/09/2026, 15:34:36

Market Cap
€88.33B
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
FR
Stock valuation chart
One-year closing share-price history for SAN.PA
Company Profile

Sanofi is a global healthcare enterprise dedicated to the research, development, manufacturing, and commercialization of therapeutic solutions across the United States, Europe, and other international markets. Its business is structured into three primary divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. The Pharmaceuticals segment delivers specialized treatments, encompassing human monoclonal antibodies and therapies for a range of conditions such as multiple sclerosis, neurological disorders, various inflammatory and immunological diseases, rare disorders, oncology, and rare blood conditions. This division also provides medications for diabetes, cardiovascular health, and a portfolio of established prescription drugs. Through its Vaccines division, Sanofi supplies crucial immunizations, including pediatric vaccines for diseases like poliomyelitis, pertussis, and Hib, alongside adult vaccines addressing influenza, booster needs, meningitis, and those required for travel or endemic regions. The Consumer Healthcare portfolio features over-the-counter remedies for common ailments such as allergies, coughs and colds, and pain relief. It also includes products for liver care, general physical and mental wellness, probiotics, digestive health, and nutritional support. Additionally, this segment offers personal care items like daily body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and powders for eczema. Sanofi maintains an active pipeline with numerous pharmaceutical products and vaccines currently undergoing various stages of development. The company has forged strategic alliances, including a collaboration with GlaxoSmithKline for the development of a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine aimed at advancing immunology and inflammation knowledge, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company operated as Sanofi-Aventis before rebranding to Sanofi in May 2011.

EUR
PAR
CEO: Belén Garijo López
Employees: 74,846
https://www.sanofi.com
Asset Summaries
Latest generated summaries for SAN.PA

No summaries found.

Detailed business
The latest official filing is available; structured extraction is pending.
SAN.PA-20-f-fy2025.html19.1 MBtext/htmlENFiled 17/02/2026Period ended 31/12/2025

The original document can be viewed now. Detailed facts and exposure relationships will appear after the separate extraction job completes.

Full company information
Latest profile, trading, valuation, and identifier data stored for SAN.PA.
Share price
€73.56
Market cap
€88.33B
Exchange
PAR
Currency
EUR
CEO
Belén Garijo López
Employees
74,846
IPO date
03/01/2000
Beta
0.28
Last dividend
€0.00
Day range
€72.90 – €74.77
52-week range
€71.25 – €91.15
1-day performance
-1.12%
1-year performance
3.24%
Current drawdown (1Y)
-19.30%
CIK
N/A
CUSIP
N/A
ISIN
FR0000120578
Created
07/09/2026, 05:15:27
Last update
23/09/2026, 15:34:36

Track Sanofi with an AI analyst

See which prediction-market events move SAN.PA, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to SAN.PA from your Railway `news_articles` table.

No news found for this symbol.